{"id":"ifo","rwe":[],"tags":[],"safety":{"boxedWarnings":[],"drugInteractions":["Mesna (reduces urotoxicity)","Cisplatin (increased nephrotoxicity)"],"commonSideEffects":[{"effect":"Nausea","drugRate":"60%","severity":"Moderate"},{"effect":"Vomiting","drugRate":"50%","severity":"Moderate"},{"effect":"Bone Marrow Suppression","drugRate":"70%","severity":"Severe"},{"effect":"Nephrotoxicity","drugRate":"30%","severity":"Severe"},{"effect":"Neurotoxicity","drugRate":"20%","severity":"Moderate"}],"contraindications":["Anemia","Bone Metastases","Bone marrow depression","Breastfeeding (mother)","CNS Toxicity","Cancer Chemotherapy Induced Hemorrhagic Cystitis","Coma","Dehydration","Disease of liver","Fanconi syndrome","Hyperbilirubinemia","Hypokalemia","Impaired cognition","Impaired wound healing","Kidney disease","Kidney excision","Leukopenia","Liver function tests abnormal","Polyneuropathies","Pregnancy, function","Renal tubular acidosis","Severe Bone Marrow Depression","Thrombocytopenic disorder"],"specialPopulations":{"Geriatric":"Increased risk of toxicity","Pregnancy":"Category D (risk to fetus)","Renal Impairment":"Dose adjustment required","Hepatic Impairment":"Monitor closely"}},"trials":[],"_chembl":{"chemblId":"CHEMBL3394332","moleculeType":"Small molecule","molecularWeight":"347.22"},"aliases":["Ifosfamide"],"patents":[],"pricing":[],"offLabel":[],"timeline":[{"date":"1980","type":"Clinical","milestone":"First clinical trials","regulator":"N/A"},{"date":"1990","type":"Commercial","milestone":"Widespread use in Europe","regulator":"EMA"}],"_dailymed":{"setId":"91e433a9-6800-43a6-ac13-a49a04a5aecd","title":"IFOSFAMIDE INJECTION, POWDER, FOR SOLUTION [BAXTER HEALTHCARE CORPORATION]"},"aiSummary":"IFO, also known as Ifosfamide, is an alkylating agent used primarily in the treatment of various cancers, particularly sarcomas. Developed by the Italian Sarcoma Group, it is not approved by the FDA and lacks a formal FDA label. The drug works by cross-linking DNA, which inhibits cell replication and leads to cell death. Common side effects include nausea, vomiting, and bone marrow suppression. Despite its efficacy, IFO has significant toxicity concerns, particularly nephrotoxicity and neurotoxicity.","ecosystem":[],"mechanism":{"target":"DNA","novelty":"Ifosfamide is a derivative of cyclophosphamide, with similar mechanisms but potentially different side effect profiles.","modality":"Chemotherapy","drugClass":"Alkylating Agent","explanation":"Ifosfamide exerts its cytotoxic effects by forming covalent bonds with DNA, leading to the formation of interstrand and intrastrand cross-links, which disrupt DNA replication and transcription.","oneSentence":"Ifosfamide is an alkylating agent that cross-links DNA, preventing cell replication and inducing apoptosis.","technicalDetail":"The active metabolite of ifosfamide, 4-hydroxyifosfamide, is converted to phosphoramide mustard and acrolein, which are responsible for the DNA cross-linking and cytotoxic effects."},"_scrapedAt":"2026-03-28T03:35:07.674Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"commercial":{"yoyGrowth":"N/A","launchDate":"N/A","annualCostUS":"N/A","currentRevenue":"N/A","patientPopulation":"N/A","peakSalesEstimate":"N/A"},"references":[],"biosimilars":[],"competitors":["Cyclophosphamide","Doxorubicin","Paclitaxel"],"indications":{"approved":[{"name":"Testicular Germ Cell Tumor","diseaseId":"testicular-germ-cell-tumor","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"}],"offLabel":["Lymphoma","Leukemia"],"pipeline":["Sarcoma","Ovarian Cancer","Testicular Cancer"]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT02306161","phase":"PHASE3","title":"Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2014-12-12","conditions":"Metastatic Ewing Sarcoma, Metastatic Malignant Neoplasm in the Bone, Metastatic Malignant Neoplasm in the Bone Marrow","enrollment":312},{"nctId":"NCT02180867","phase":"PHASE2, PHASE3","title":"Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2014-07-11","conditions":"Alveolar Soft Part Sarcoma, Angiomatoid Fibrous Histiocytoma, Atypical Fibroxanthoma","enrollment":140},{"nctId":"NCT04881838","phase":"PHASE3","title":"CCCG-ALCL-2020 for Chinese Children and Adolescents With Newly Diagnosed High-risk ALCL","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Cancer Group, China","startDate":"2021-03-01","conditions":"Pediatric Anaplastic Large Cell Lymphoma","enrollment":172},{"nctId":"NCT05681260","phase":"PHASE3","title":"Capizzi Escalating Methotrexate Versus High Dose Methotrexate in Children With Newly Diagnosed T-cell Lymphoblastic Lymphoma (T-LBL)","status":"RECRUITING","sponsor":"Children's Cancer Group, China","startDate":"2023-02-06","conditions":"T-cell Lymphoblastic Lymphoma","enrollment":200},{"nctId":"NCT03418038","phase":"PHASE2","title":"Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2018-03-23","conditions":"Clonal Cytopenia of Undetermined Significance, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Recurrent Diffuse Large B-Cell Lymphoma","enrollment":80},{"nctId":"NCT02845882","phase":"PHASE3","title":"LBL-2016 for Children or Adolescents in China","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Cancer Group, China","startDate":"2016-01","conditions":"Lymphoblastic Lymphoma","enrollment":150},{"nctId":"NCT04031677","phase":"PHASE3","title":"Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma","status":"RECRUITING","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2021-01-20","conditions":"Retroperitoneal Sarcoma, Liposarcoma, Leiomyosarcoma","enrollment":250},{"nctId":"NCT05813327","phase":"PHASE1","title":"Neoadjuvant ADI-PEG 20 + Ifosfamide + Radiotherapy in Soft Tissue Sarcoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2024-03-14","conditions":"Soft Tissue Sarcoma, Sts, Sarcoma,Soft Tissue","enrollment":6},{"nctId":"NCT07477457","phase":"PHASE2","title":"A Study of Gefitinib, Trametinib, Disulfiram, and Sunitinib in Addition to Standard Chemotherapy in People With Osteosarcoma","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2026-03-11","conditions":"Osteosarcoma, Metastasis","enrollment":45},{"nctId":"NCT07194044","phase":"PHASE1","title":"Metastatic Ewing's Trial Testing Schedule Enhancement to Improve Outcomes","status":"RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2026-02","conditions":"Metastatic Ewing Sarcoma","enrollment":15},{"nctId":"NCT03458260","phase":"PHASE2","title":"Study of Pixantrone in CD20+ Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma","status":"COMPLETED","sponsor":"The Lymphoma Academic Research Organisation","startDate":"2018-12-26","conditions":"Aggressive Non-Hodgkin Lymphoma","enrollment":74},{"nctId":"NCT05533775","phase":"PHASE1, PHASE2","title":"A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2022-11-16","conditions":"Mature B-Cell Non-Hodgkin Lymphoma","enrollment":65},{"nctId":"NCT03849651","phase":"PHASE2","title":"TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2019-01-31","conditions":"Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS)","enrollment":69},{"nctId":"NCT04663347","phase":"PHASE1, PHASE2","title":"Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Genmab","startDate":"2020-11-03","conditions":"Diffuse Large B-Cell Lymphoma, Follicular Lymphoma","enrollment":543},{"nctId":"NCT04486391","phase":"PHASE3","title":"Tislelizumab Monotherapy Versus Salvage Chemotherapy for Relapsed/Refractory Classical Hodgkin Lymphoma","status":"TERMINATED","sponsor":"BeiGene","startDate":"2020-12-14","conditions":"Classical Hodgkin Lymphoma","enrollment":3},{"nctId":"NCT06647953","phase":"PHASE3","title":"Testing a Standardized Approach to Surgery and Chemotherapy for Type I Pleuropulmonary Blastoma or the Addition of an Anti-cancer Drug, Topotecan, to the Usual Treatment for Types II and III Pleuropulmonary Blastoma","status":"RECRUITING","sponsor":"Children's Oncology Group","startDate":"2025-03-21","conditions":"Pleuropulmonary Blastoma","enrollment":110},{"nctId":"NCT04684368","phase":"PHASE2","title":"A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT","status":"RECRUITING","sponsor":"Children's Oncology Group","startDate":"2021-07-13","conditions":"Central Nervous System Nongerminomatous Germ Cell Tumor, Choriocarcinoma, Embryonal Carcinoma","enrollment":160},{"nctId":"NCT04322318","phase":"PHASE2","title":"A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT","status":"RECRUITING","sponsor":"Children's Oncology Group","startDate":"2020-10-19","conditions":"Anaplastic Kidney Wilms Tumor, Recurrent Kidney Wilms Tumor, Stage II Kidney Wilms Tumor","enrollment":256},{"nctId":"NCT01946529","phase":"PHASE2","title":"Therapeutic Trial for Patients With Ewing Sarcoma Family of Tumor and Desmoplastic Small Round Cell Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2013-12-27","conditions":"Desmoplastic Small Round Cell Tumor, Ewing Sarcoma of Bone or Soft Tissue, Localized Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor","enrollment":24},{"nctId":"NCT03007147","phase":"PHASE3","title":"Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2017-08-08","conditions":"Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, Mixed Phenotype Acute Leukemia","enrollment":475},{"nctId":"NCT05991388","phase":"PHASE2, PHASE3","title":"A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin Lymphoma","status":"RECRUITING","sponsor":"University of Birmingham","startDate":"2024-05-02","conditions":"B-cell Non Hodgkin Lymphoma","enrollment":210},{"nctId":"NCT04199026","phase":"NA","title":"Implantable Microdevice for the Delivery of Drugs and Their Effect on Tumors in Patients With Metastatic or Recurrent Sarcoma","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2025-02-25","conditions":"Metastatic Sarcoma, Recurrent Sarcoma, Resectable Sarcoma","enrollment":20},{"nctId":"NCT04570423","phase":"PHASE2","title":"A Study to Evaluate the Safety and Pharmacokinetics of Eflapegrastim in Pediatric Participants With Solid Tumors or Lymphomas and Treated With Myelosuppressive Chemotherapy","status":"RECRUITING","sponsor":"Spectrum Pharmaceuticals, Inc","startDate":"2021-05-20","conditions":"Solid Tumors, Lymphoma","enrollment":40},{"nctId":"NCT06820957","phase":"PHASE2, PHASE3","title":"Testing a New Combination of Anti-cancer Drugs in Patients Newly Diagnosed With Ewing Sarcoma Who Have Cancer That Has Spread to Other Parts of the Body","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2025-11-10","conditions":"CIC-Rearranged Sarcoma, Metastatic Ewing Sarcoma, Metastatic High Grade Sarcoma","enrollment":437},{"nctId":"NCT07405346","phase":"NA","title":"A Trial for Advanced Leiomyosarcoma With Human Organoid-guided Personalized Efficacy","status":"ENROLLING_BY_INVITATION","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2026-03-01","conditions":"Advanced Leiomyosarcoma","enrollment":50},{"nctId":"NCT04307277","phase":"PHASE3","title":"Interest of Peri Operative CHemotherapy In Patients With CINSARC High-risk Localized Soft Tissue Sarcoma","status":"RECRUITING","sponsor":"Institut Claudius Regaud","startDate":"2020-10-09","conditions":"Soft Tissue Sarcoma","enrollment":600},{"nctId":"NCT06528496","phase":"PHASE2","title":"N10: A Study of Reduced Chemotherapy and Monoclonal Antibody (mAb)-Based Therapy in Children With Neuroblastoma","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2024-07-22","conditions":"High-risk Neuroblastoma, Neuroblastoma, Childhood Neuroblastoma","enrollment":45},{"nctId":"NCT06230224","phase":"PHASE3","title":"A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell Non-Hodgkin Lymphoma","status":"RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2024-02-15","conditions":"B-Cell Non-Hodgkin Lymphoma (B-NHL)","enrollment":216},{"nctId":"NCT07389356","phase":"NA","title":"Modified R-MINE Regimen vs. R-GemOx Regimens on the Treatment of Late Relapsed DLBCL","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2026-02-25","conditions":"DLBCL - Diffuse Large B Cell Lymphoma","enrollment":70},{"nctId":"NCT01959698","phase":"PHASE1","title":"Carfilzomib, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Stage I-IV Diffuse Large B-cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Roswell Park Cancer Institute","startDate":"2014-04-17","conditions":"CD20 Positive, Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma","enrollment":29},{"nctId":"NCT06239272","phase":"PHASE1, PHASE2","title":"NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)","status":"RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2024-03-27","conditions":"Adipocytic Neoplasm, Liposarcoma, Atypical Fibroxanthoma","enrollment":139},{"nctId":"NCT01231906","phase":"PHASE3","title":"Combination Chemotherapy in Treating Patients With Non-Metastatic Extracranial Ewing Sarcoma","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2010-11-24","conditions":"Localized Extraskeletal Ewing Sarcoma, Peripheral Primitive Neuroectodermal Tumor of Bone, Peripheral Primitive Neuroectodermal Tumor of Soft Tissues","enrollment":642},{"nctId":"NCT07321912","phase":"PHASE2","title":"Eflornithine (DFMO) for Ewing Sarcoma and Osteosarcoma","status":"NOT_YET_RECRUITING","sponsor":"Milton S. Hershey Medical Center","startDate":"2026-04-01","conditions":"Osteosarcoma, Ewing Sarcoma, Ewing Sarcoma Metastatic","enrollment":406},{"nctId":"NCT06849986","phase":"PHASE2","title":"IO Combined With AI as First-line Treatment for Patients With Soft Tissue Sarcoma(TAIS)","status":"RECRUITING","sponsor":"Fudan University","startDate":"2025-02-25","conditions":"Soft Tissue Sarcomas, Angiosarcoma, Fibrosarcoma","enrollment":45},{"nctId":"NCT02106988","phase":"PHASE2","title":"Concurrent Chemotherapy and Radiation Therapy for Newly Diagnosed Nasal NK Cell Lymphoma","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2015-01-16","conditions":"Lymphoma","enrollment":40},{"nctId":"NCT04425070","phase":"PHASE1, PHASE2","title":"A Study of Evaluating the Safety and Efficacy of ATG-010 Combined With Chemotherapy Sequential With ATG-010 Monotherapy Maintenance in Peripheral T- and NK/T-cell Lymphoma","status":"TERMINATED","sponsor":"Antengene Corporation","startDate":"2020-08-18","conditions":"Peripheral T-cell Lymphoma, NK/T-cell Lymphoma","enrollment":56},{"nctId":"NCT04224337","phase":"PHASE2","title":"Phase II Study of Durvalumab ,Doxorubicin, and Ifosfamide in Pulmonary Sarcomatoid Carcinoma","status":"COMPLETED","sponsor":"Seoul National University Hospital","startDate":"2020-06-11","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":16},{"nctId":"NCT06835049","phase":"PHASE2","title":"Feasibility of Total Neoadjuvant Treatment With HYPErthermia in Patients With High-risk Extremity and Trunk Soft Tissue Sarcoma (TNT-HYPE)","status":"RECRUITING","sponsor":"Swiss Cancer Institute","startDate":"2025-10-27","conditions":"Sarcoma,Soft Tissue","enrollment":24},{"nctId":"NCT03643133","phase":"PHASE2","title":"Mifamurtide Combined With Post-operative Chemotherapy for Newly Diagnosed High Risk Osteosarcoma Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"UNICANCER","startDate":"2018-10-23","conditions":"Osteosarcoma","enrollment":60},{"nctId":"NCT04881240","phase":"PHASE1","title":"Study of CD19-directed Allogeneic Memory T-cell Therapy for Relapsed/Refractory CD19+ Leukemia","status":"RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2024-02-14","conditions":"Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia, Refractory, Pediatric ALL","enrollment":60},{"nctId":"NCT01871766","phase":"PHASE2","title":"Risk-Adapted Focal Proton Beam Radiation and/or Surgery in Patients With Low, Intermediate and High Risk Rhabdomyosarcoma Receiving Standard or Intensified Chemotherapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2013-12-04","conditions":"Rhabdomyosarcoma","enrollment":115},{"nctId":"NCT06520163","phase":"PHASE3","title":"Comparison Study of EAP and Disease-Specific Chemotherapy Regimens in Hematopoietic Stem Cell Mobilization for Lymphoma","status":"RECRUITING","sponsor":"The Affiliated People's Hospital of Ningbo University","startDate":"2024-08-01","conditions":"Non-Hodgkin's Lymphoma, Hematopoietic Stem Cell Mobilization","enrollment":99},{"nctId":"NCT06333314","phase":"PHASE2","title":"Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSI","status":"RECRUITING","sponsor":"UNICANCER","startDate":"2024-07-23","conditions":"Pancreatic Adenocarcinoma, Ampulla of Vater Carcinoma, Adrenocortical Carcinoma","enrollment":120},{"nctId":"NCT02789384","phase":"NA","title":"CINSARC Signature and Correlation With Hemotherapy Efficacy in Soft-tissue Sarcomas. A Biomarker Study.","status":"RECRUITING","sponsor":"Institut Bergonié","startDate":"2016-06","conditions":"Soft-tissue Sarcomas","enrollment":205},{"nctId":"NCT02112916","phase":"PHASE3","title":"Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2014-10-04","conditions":"Adult T Acute Lymphoblastic Leukemia, Ann Arbor Stage II Adult Lymphoblastic Lymphoma, Ann Arbor Stage II Childhood Lymphoblastic Lymphoma","enrollment":847},{"nctId":"NCT05364424","phase":"PHASE1","title":"A Study Evaluating the Efficacy, Safety, and Pharmacokinetics of Glofitamab in Combination With Rituximab Plus Ifosfamide, Carboplatin Etoposide Phosphate in Participants With Relapsed/Refractory Transplant or CAR-T Therapy Eligible Diffuse B-Cell Lymphoma","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2022-11-04","conditions":"Diffuse Large B-Cell Lymphoma (DLBCL)","enrollment":43},{"nctId":"NCT03391466","phase":"PHASE3","title":"Study of Effectiveness of Axicabtagene Ciloleucel Compared to Standard of Care Therapy in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma","status":"COMPLETED","sponsor":"Kite, A Gilead Company","startDate":"2018-01-25","conditions":"Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)","enrollment":359},{"nctId":"NCT04388839","phase":"PHASE2","title":"Evolutionary Therapy for Rhabdomyosarcoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2020-12-29","conditions":"Rhabdomyosarcoma","enrollment":12},{"nctId":"NCT07243626","phase":"PHASE2","title":"Efficacy and Safety of Envafolimab Plus Doxorubicin and Ifosfamide for Advanced Soft Tissue Sarcoma","status":"NOT_YET_RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2025-12-30","conditions":"Soft Tissue Sarcoma","enrollment":15},{"nctId":"NCT03011528","phase":"PHASE2","title":"First-line Treatment of Ewing Tumours With Primary Extrapulmonary Dissemination in Patients From 2 to 50 Years (CombinaiR3)","status":"COMPLETED","sponsor":"Institut Curie","startDate":"2016-12","conditions":"Ewing Sarcoma Family of Tumors","enrollment":45},{"nctId":"NCT01602666","phase":"PHASE2","title":"Chemotherapy Followed by Radiation Therapy in Treating Younger Patients With Newly Diagnosed Localized Central Nervous System Germ Cell Tumors","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2012-06-27","conditions":"Central Nervous System Nongerminomatous Germ Cell Tumor, Childhood Germinoma","enrollment":262},{"nctId":"NCT05821088","phase":"PHASE2","title":"Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patients With Relapsed/ Refractory Large B-Cell Lymphoma","status":"RECRUITING","sponsor":"David Bond, MD","startDate":"2023-06-29","conditions":"Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent Grade 3b Follicular Lymphoma","enrollment":37},{"nctId":"NCT02227199","phase":"PHASE1, PHASE2","title":"Brentuximab Vedotin, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma","status":"COMPLETED","sponsor":"University of Washington","startDate":"2014-10-10","conditions":"Recurrent Hodgkin Lymphoma, Refractory Hodgkin Lymphoma","enrollment":45},{"nctId":"NCT01710176","phase":"PHASE3","title":"Localized High-Risk Soft Tissue Sarcomas Of The Extremities And Trunk Wall In Adults: An Integrating Approach Comprising Standard Vs Histotype-Tailored Neoadjuvant Chemotherapy","status":"COMPLETED","sponsor":"Italian Sarcoma Group","startDate":"2011-06-01","conditions":"Localized High-risk Soft Tissue Sarcomas of the Extremities and Trunk Wall in Adults","enrollment":550},{"nctId":"NCT06156410","phase":"PHASE1","title":"Cabozantinib With Ifosfamide in Relapsed/Refractory Sarcomas","status":"RECRUITING","sponsor":"Children's Hospital of Philadelphia","startDate":"2023-10-24","conditions":"Ewing Sarcoma, Osteosarcoma, Sarcomas","enrollment":30},{"nctId":"NCT01864109","phase":"PHASE2","title":"Irinotecan and Temozolomide in Combination With Existing High Dose Alkylator Based Chemotherapy for Treatment of Patients With Newly Diagnosed Ewing Sarcoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2013-05","conditions":"Newly Diagnosed Ewing Sarcoma","enrollment":83},{"nctId":"NCT00077285","phase":"PHASE2","title":"Irinotecan and Carboplatin as Upfront Window Therapy in Treating Patients With Newly Diagnosed Intermediate-Risk or High-Risk Rhabdomyosarcoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2003-10","conditions":"Sarcoma","enrollment":65},{"nctId":"NCT04897321","phase":"PHASE1","title":"B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)","status":"RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2022-07-06","conditions":"Pediatric Solid Tumor, Osteosarcoma, Rhabdomyosarcoma","enrollment":32},{"nctId":"NCT04318678","phase":"PHASE1","title":"CD123-Directed T-Cell Therapy for Acute Myelogenous Leukemia (CATCHAML)","status":"RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2020-07-29","conditions":"AML/MDS, B-ALL, T-ALL","enrollment":108},{"nctId":"NCT01508312","phase":"PHASE2","title":"Brentuximab Vedotin (SGN-35) in Transplant Eligible Patients With Relapsed or Refractory Hodgkin Lymphoma","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2012-01-05","conditions":"Hodgkin's Lymphoma","enrollment":66},{"nctId":"NCT03016871","phase":"PHASE2","title":"Nivolumab, Ifosfamide, Carboplatin, and Etoposide as Second-Line Therapy in Treating Patients With Refractory or Relapsed HL","status":"ACTIVE_NOT_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2017-04-24","conditions":"Recurrent Hodgkin Lymphoma, Refractory Hodgkin Lymphoma","enrollment":78},{"nctId":"NCT03805022","phase":"PHASE3","title":"Benefit of Intensified Peri-operative Chemotherapy Within High-risk CINSARC Patients With Resectable Soft-tissue Sarcomas","status":"RECRUITING","sponsor":"Institut Bergonié","startDate":"2019-02-14","conditions":"Non-metastatic Soft-tissue Sarcoma, Resectable","enrollment":351},{"nctId":"NCT04833114","phase":"PHASE3","title":"Polatuzumab Vedotin Plus Rituximab, Ifosfamide, Carboplatin and Etoposide (Pola-R-ICE) Versus R-ICE Alone in Second Line Treatment of Diffuse Large B-cell Lymphoma (DLBCL)","status":"ACTIVE_NOT_RECRUITING","sponsor":"GWT-TUD GmbH","startDate":"2021-04-30","conditions":"Relapsed Diffuse Large B-cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma","enrollment":306},{"nctId":"NCT06905509","phase":"PHASE2","title":"Epcoritamab Plus Standard of Care Platinum-Based Chemotherapy and Autologous Hematopoietic Cell Transplant for the Treatment of Relapsed or Refractory Large B-cell Lymphoma","status":"RECRUITING","sponsor":"Joseph Tuscano","startDate":"2025-07-31","conditions":"Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements","enrollment":25},{"nctId":"NCT07187960","phase":"PHASE3","title":"Evaluation of the Efficacy and Safety of TQB2825 Injection Compared to Immunotherapy in the Treatment of Recurrent/Refractory Follicular Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.","startDate":"2025-11","conditions":"Follicular Lymphoma","enrollment":228},{"nctId":"NCT06341998","phase":"PHASE2, PHASE3","title":"Clinical Study of Chemotherapy in the Treatment of Recurrent/Refractory Yolk Sac Tumor in Children","status":"COMPLETED","sponsor":"Shandong First Medical University","startDate":"2020-06-01","conditions":"Germ Cell Tumor, Yolk Sac Tumor","enrollment":32},{"nctId":"NCT07156643","phase":"PHASE2","title":"A Prospective, Single-arm, Multicenter Exploratory Clinical Study of Anlotinib Combined With Bempegaldesleukin and Conventional Chemoradiotherapy for the Treatment of Unresectable Locally Advanced or Metastatic Soft Tissue Sarcoma.","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2025-10-01","conditions":"Locally Advanced Soft Tissue Sarcoma","enrollment":46},{"nctId":"NCT04665765","phase":"PHASE2","title":"Polatuzumab Vedotin, Rituximab, Ifosfamide, Carboplatin, and Etoposide (PolaR-ICE) as Initial Salvage Therapy for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2021-01-18","conditions":"Diffuse Large B-Cell Lymphoma Unclassifiable, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma","enrollment":41},{"nctId":"NCT01703754","phase":"PHASE2","title":"Adenoviral Vector Monotherapy or Combination With Chemotherapy in Subjects With Recurrent/Metastatic Breast Cancer.","status":"TERMINATED","sponsor":"Alaunos Therapeutics","startDate":"2013-04-04","conditions":"Breast Cancer Nos Metastatic Recurrent","enrollment":12},{"nctId":"NCT07142863","phase":"PHASE2","title":"Envafolimab Combined With Neoadjuvant Chemotherapy Treat Stage IIb Resectable Osteosarcoma Patients","status":"NOT_YET_RECRUITING","sponsor":"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","startDate":"2025-08-25","conditions":"Osteosarcoma, Neoadjuvant Therapy, Neoadjuvant Chemotherapy","enrollment":23},{"nctId":"NCT07081022","phase":"PHASE2","title":"JS203 Combination Regimens in B-Cell Non-Hodgkin's Lymphoma","status":"RECRUITING","sponsor":"Shanghai Junshi Bioscience Co., Ltd.","startDate":"2025-08-17","conditions":"B-cell Non-Hodgkin's Lymphoma","enrollment":180},{"nctId":"NCT04776525","phase":"PHASE2","title":"Sequential Neoadjuvant Chemotherapy in Soft Tissue Sarcoma","status":"RECRUITING","sponsor":"Oslo University Hospital","startDate":"2021-04-27","conditions":"Soft Tissue Sarcoma","enrollment":49},{"nctId":"NCT04968106","phase":"PHASE2","title":"Neoadjuvant Chemotherapy and Retifanlimab in Patients With Selected Sarcomas (TORNADO)","status":"RECRUITING","sponsor":"Institut Bergonié","startDate":"2022-12-07","conditions":"Resectable Sarcoma","enrollment":66},{"nctId":"NCT02393157","phase":"PHASE2","title":"Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL","status":"RECRUITING","sponsor":"New York Medical College","startDate":"2015-08-21","conditions":"Non-Hodgkin Lymphoma, Burkitt Lymphoma, Diffuse Large B-Cell Lymphoma","enrollment":25},{"nctId":"NCT03719105","phase":"EARLY_PHASE1","title":"Chemoimmunotherapy and Allogeneic Stem Cell Transplant for NK T-cell Leukemia/Lymphoma","status":"RECRUITING","sponsor":"New York Medical College","startDate":"2019-03-01","conditions":"NK-Cell Lymphoma, NK-Cell Leukemia, Peripheral T Cell Lymphoma","enrollment":40},{"nctId":"NCT04947501","phase":"EARLY_PHASE1","title":"A Study of N9 Chemotherapy in Children With Neuroblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2021-06-22","conditions":"Neuroblastoma, Pediatric Cancer","enrollment":26},{"nctId":"NCT06418789","phase":"PHASE2","title":"High-dose Chemotherapy as Second-line Drug Therapy for Relapsed Germ Cell Tumors","status":"RECRUITING","sponsor":"N.N. Petrov National Medical Research Center of Oncology","startDate":"2024-03-01","conditions":"Germ Cell Tumor","enrollment":25},{"nctId":"NCT07102199","phase":"NA","title":"Effect of Attentional Focus Order in Home Exercise for Neck Pain","status":"ACTIVE_NOT_RECRUITING","sponsor":"Büşra Tamgüç","startDate":"2025-05-01","conditions":"Neck Pain, Motor Learning, Home Exercise Program","enrollment":39},{"nctId":"NCT01979393","phase":"PHASE2","title":"IRCI Gynae Sarcomas, High Grade Uterine Sarcoma","status":"COMPLETED","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2015-02-02","conditions":"Uterine Sarcoma","enrollment":58},{"nctId":"NCT06277154","phase":"PHASE2","title":"MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma","status":"RECRUITING","sponsor":"HRYZ Biotech Co.","startDate":"2024-02-21","conditions":"Leiomyosarcoma, Liposarcoma, Synovial Sarcoma","enrollment":148},{"nctId":"NCT03034304","phase":"PHASE1","title":"A Phase I Clinical Study for Evaluating the Safety and Efficacy of MASCT-I in Patients With Advanced Solid Tumors","status":"TERMINATED","sponsor":"HRYZ Biotech Co.","startDate":"2017-02-22","conditions":"Advanced Solid Tumors","enrollment":105},{"nctId":"NCT00878254","phase":"PHASE2","title":"Rituximab and Combination Chemotherapy in Treating Patients With Previously Untreated Mantle Cell Lymphoma","status":"COMPLETED","sponsor":"University of Miami","startDate":"2009-03-25","conditions":"Mantle-Cell Lymphoma","enrollment":25},{"nctId":"NCT06220097","phase":"PHASE2","title":"Mitoxantrone Hydrochloride Liposome Injection-containing Bridging Regimen and CD19-targeting CAR-T Therapies","status":"ACTIVE_NOT_RECRUITING","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2022-02-01","conditions":"B-cell Acute Lymphoblastic Leukemia, B-cell Lymphoma Refractory","enrollment":28},{"nctId":"NCT02329080","phase":"PHASE2","title":"New Combination of Chemoimmunotherapy for Systemic B-cell Lymphoma With Central Nervous System Involvement","status":"COMPLETED","sponsor":"International Extranodal Lymphoma Study Group (IELSG)","startDate":"2014-12","conditions":"Diffuse Large B-cell Lymphoma","enrollment":79},{"nctId":"NCT01873326","phase":"PHASE2","title":"Paclitaxel, Ifosfamide and Cisplatin (TIP) Versus Bleomycin, Etoposide and Cisplatin (BEP) for Patients With Previously Untreated Intermediate- and Poor-risk Germ Cell Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2013-06","conditions":"Germ Cell Tumors","enrollment":92},{"nctId":"NCT02817958","phase":"PHASE2","title":"Evaluation of Lymphadenectomy and Chemotherapy TIP on Inguinal Lymph Nodes in Squamous Cell Carcinoma of the Penis","status":"ACTIVE_NOT_RECRUITING","sponsor":"UNICANCER","startDate":"2016-10-17","conditions":"Penile Cancer, Squamous Carcinoma","enrollment":37},{"nctId":"NCT04221035","phase":"PHASE3","title":"High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)","status":"RECRUITING","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2019-11-05","conditions":"High-Risk Neuroblastoma, Patient With Insufficient Response Chemoimmunotherapy","enrollment":800},{"nctId":"NCT02324296","phase":"","title":"PEI REGIMEN: A Therapeutic Option in Small Cell Lung Cancer? A Monoinstitutional Experience of 46 Consecutive Cases","status":"COMPLETED","sponsor":"Azienda USL Reggio Emilia - IRCCS","startDate":"1998-12","conditions":"Small Cell Lung Cancer","enrollment":46},{"nctId":"NCT00470223","phase":"PHASE3","title":"Combined Chemotherapy With or Without Zoledronic Acid for Patients With Osteosarcoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"UNICANCER","startDate":"2007-03","conditions":"Sarcoma","enrollment":318},{"nctId":"NCT05827549","phase":"PHASE2","title":"Evaluation of Treatment Efficacy According to Risk Group in Relapsed Childhood Acute Lymphoblastic Leukemia","status":"RECRUITING","sponsor":"Ho Joon Im","startDate":"2024-04-04","conditions":"Acute Lymphoid Leukemia","enrollment":90},{"nctId":"NCT04189952","phase":"PHASE2","title":"Acalabrutinib in Combination With R-ICE For Relapsed or Refractory Lymphoma","status":"TERMINATED","sponsor":"University of Miami","startDate":"2020-09-22","conditions":"Diffuse Large B Cell Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia","enrollment":2},{"nctId":"NCT05705687","phase":"NA","title":"Validation of a Treatment Algorithm for Poor-Risk NSGCTnon Seminomatous Germ-cell Tumors","status":"RECRUITING","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2023-05-05","conditions":"Non-Seminomatous Germ Cell Tumor","enrollment":150},{"nctId":"NCT04668365","phase":"PHASE2","title":"Zanubrutinib Combined With Standard Chemotherapy in the Treatment for Patients With Diffuse Large B Cell Lymphoma","status":"SUSPENDED","sponsor":"Henan Cancer Hospital","startDate":"2020-12-25","conditions":"Diffuse Large B Cell Lymphoma, CD79A Gene Mutation, CD79B Gene Mutation","enrollment":59},{"nctId":"NCT06415318","phase":"PHASE2","title":"TIP Regimen Combined With Triplizumab Neoadjuvant Therapy for Locally Advanced Penile Cancer","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2024-05-31","conditions":"Penile Cancer","enrollment":25},{"nctId":"NCT03643276","phase":"PHASE3","title":"Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017","status":"RECRUITING","sponsor":"Martin Schrappe","startDate":"2018-07-15","conditions":"Acute Lymphoblastic Leukemia, Pediatric","enrollment":5000},{"nctId":"NCT02305654","phase":"PHASE3","title":"International Penile Advanced Cancer Trial (International Rare Cancers Initiative Study)","status":"RECRUITING","sponsor":"Institute of Cancer Research, United Kingdom","startDate":"2017-05-12","conditions":"Squamous Cell Carcinoma of the Penis, Usual Type","enrollment":200},{"nctId":"NCT05427136","phase":"","title":"Early Pulmonary Dysfunction in Childhood Cancer Patients","status":"RECRUITING","sponsor":"University Children's Hospital Basel","startDate":"2021-06-01","conditions":"Pulmonary Dysfunction","enrollment":140},{"nctId":"NCT03440567","phase":"PHASE1","title":"Avelumab, Utomilumab, Rituximab, Ibrutinib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma","status":"COMPLETED","sponsor":"City of Hope Medical Center","startDate":"2018-04-02","conditions":"Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Mantle Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma","enrollment":16},{"nctId":"NCT03206671","phase":"PHASE3","title":"Treatment Protocol of the NHL-BFM and the NOPHO Study Groups for Mature Aggressive B-cell Lymphoma and Leukemia in Children and Adolescents","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Hospital Muenster","startDate":"2017-08-03","conditions":"Mature B-cell Non-Hodgkin Lymphoma","enrollment":650},{"nctId":"NCT04043494","phase":"PHASE3","title":"International Cooperative Treatment Protocol for Children and Adolescents With Lymphoblastic Lymphoma","status":"RECRUITING","sponsor":"University Hospital Muenster","startDate":"2019-08-23","conditions":"Lymphoblastic Lymphoma, Childhood","enrollment":683}],"_emaApprovals":[],"_faersSignals":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"formularyStatus":[],"_approvalHistory":[],"developmentCodes":[],"ownershipHistory":[],"publicationCount":1260,"therapeuticAreas":["Oncology"],"biosimilarFilings":[],"companionDiagnostics":[],"genericManufacturerList":[],"phase":"marketed","status":"active","brandName":"IFO","genericName":"IFO","companyName":"Italian Sarcoma Group","companyId":"italian-sarcoma-group","modality":"Small molecule","firstApprovalDate":"N/A","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}